Document Type : Original Article
Authors
1 Professor, Neuroscience Research Center, Neuropharmacology Institute AND Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 Psychiatrist, Neuroscience Research Center, Neuropharmacology Institute AND Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
3 PhD Student, HIV/STI Surveillance Research Center AND WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
4 Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Ir
5 Associate Professor, Neuroscience Research Center, Neuropharmacology Institute AND Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Abstract
Keywords
10. Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC. Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Drug Alcohol Depend 2015; 151: 47-55.
11. Mauger S, Fraser R, Gill K. Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat 2014; 10: 587-98.
12. Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, Freese T, et al. From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat 2010; 38(Suppl 1): S53-S60.
13. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998; 50(1): 1-8.
14. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20(9): 697-712.
15. Orman JS, Keating GM. Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs 2009; 69(5): 577-607.
16. Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 2008; 3: 16.
17. Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011; 89(3): 443-9.
18. Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine-naloxone (suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addict Med 2007; 1(2): 104-10.
19. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009; 24(2): 226-32.